Atombeat and BioDuro link for peptide drug discovery platform
Atombeat and BioDuro have announced a strategic partnership to launch an AI-powered platform aimed at accelerating peptide drug discovery. The…
All articles by Srivani Venna
Srivani Venna
-
-
Arrowhead sells China hypertriglyceridemia candidate rights to Sanofi
Arrowhead Pharmaceuticals’ subsidiary Visirna Therapeutics has entered an asset purchase agreement with Sanofi for the rights to develop and commercialise…
-
Sanofi’s Sarclisa gains EC approval for multiple myeloma treatment
The European Commission (EC) has granted approval to Sanofi's Sarclisa in combination with a regimen of bortezomib, lenalidomide and dexamethasone…
-
Hengrui Pharma and GSK link across key therapeutic areas
Hengrui Pharma has signed an agreement with GSK for the development of up to 12 innovative medicines across several therapeutic…
-
Swissmedic approves Novartis’ malaria medicine for babies
The Swiss Agency for Therapeutic Products (Swissmedic) has approved Novartis’ Coartem (artemether-lumefantrine) Baby, described as the first malaria medicine for…
-
GSK acquires efimosfermin alfa from Boston Pharma for $2bn
GSK has concluded the acquisition of efimosfermin alfa, an investigational therapeutic for serious liver disease (SLD), from Boston Pharmaceuticals in…
-
Torrent Pharmaceuticals to acquire stake in JB Pharma for $3bn
Torrent Pharmaceuticals, headquartered in Gujerat, India, has signed definitive agreements for the acquisition of a controlling stake in JB Chemicals…
-
Sanofi begins shipping BEYFORTUS to US for RSV prevention in infants
French multinational pharmaceutical company Sanofi has commenced the shipping of BEYFORTUS (nirsevimab-alip) to the US, targeting both private healthcare providers…
-
SBTi approves Piramal Pharma’s GHG reduction targets
The Science Based Targets initiative (SBTi) has validated and approved India's Piramal Pharma’s near-term greenhouse gas (GHG) emission reduction targets.…
-
Regeneron’s Dupixent approved as first adolescent CRSwNP treatment
The US Food and Drug Administration (FDA) has expanded the approval of Dupixent (dupilumab) to include adolescents aged 12 to…